Anti‐programmed death ligand 1 therapy‐induced type 1 diabetes presenting with multiple islet‐related autoantibodies

Honoki, Hisae; Yagi, Kunimasa; Kambara, Kenta; Chujo, Daisuke; Shikata, Masataka; Enkaku, Asako; Takikawa-Nishida, Akiko; Liu, Jianhui; Fujisaka, Shiho; Tobe, Kazuyuki

doi:10.1111/jdi.13099

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pd-1/pd-l1 In Other Diseases1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated PD-L1 expression is found in islet β-cells and may restrict autoreactive T cells activation in pancreas. 98,99 In the nonobese diabetics (NOD) mice, which are a spontaneous model of T1DM and genetically similar and comparable to diabetic patients, PD-1 acts as a protective factor. Forced expression of PD-1 in transgenic mice significantly reduces the incidence of autoimmune diabetes.…”

Section: Pd-1/pd-l1 In Other Diseasesmentioning

confidence: 99%

PD‐1/PD‐L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity

Hosseinzadeh

Feizisani²,

Shomali

et al. 2021

IUBMB Life

View full text Add to dashboard Cite

Immune checkpoint blockade therapy (ICBT) has become a successful cancer treatment approach in the field of cancer immunotherapy. Blockade of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) with monoclonal antibodies have been known as successful examples of cancer immunotherapy in recent years. Although ICBT has been shown to be beneficial in cancers, such benefits have only been seen in a portion of cancer patients. In this regard, enhancing the therapeutic effects of inhibiting PD-1 and PD-L1 and reducing the side effects of this approach can be considered as

show abstract

Section: Pd-1/pd-l1 In Other Diseasesmentioning

confidence: 99%